跳至主要内容
临床试验/RPCEC00000284
RPCEC00000284招募中未知

Evaluation of the behavior of platelets count, EGF serum concentrations and the levels of lymphocytes subpopulations expression associated with the patient's immune status as possible biomarkers of effectiveness of CIMAvax-EGF vaccine.

Center of Molecular Immunology (CIM)0 个研究点开始时间: 2018年8月3日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment

入排标准

年龄范围
18 years 至 one(—)
性别
All

入选标准

  • 1. Patients of any sex and age similar or more than 18 years.
  • 2. Patients that complete the diagnostic criteria.
  • 3. Patients included in another clinical trial in which the therapeutic vaccine CIMAvax-EGF® is administered, or that they don't receive products in investigation and be managed follow up the Cuban Guide of treatment of patient with lung cancer 2016 version.
  • 4. Patient that have signed the informed consent for the investigation.
  • 5. Patient with performan status (ECOG) state from 0 at 3

排除标准

  • 1. Patient in fertile age that are not using an appropriate (intra-uterine devices, hormonal contraceptives, barrier methods or bond of trumpets) method of contraception. For the males (vasectomy, use of preservatives) while the treatment lasts
  • 2. Pregnant, lactating or puerperal patients.

研究者

发起方
Center of Molecular Immunology (CIM)

相似试验

CIMAvax-EGF-Platelets-Adults- Lung Cancer | 临床试验